Pacritinib
- Generic Name
- Pacritinib
- Brand Names
- Vonjo
- Drug Type
- Small Molecule
- Chemical Formula
- C28H32N4O3
- CAS Number
- 937272-79-2
- Unique Ingredient Identifier
- G22N65IL3O
- Background
Myelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within the bone marrow. The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia. While some patients may remain asymptomatic, typical symptoms of MF arise from abnormali...
- Indication
Pacritinib is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10/L.
...
- Associated Conditions
- High-Risk Secondary Myelofibrosis, High risk Primary Myelofibrosis (PMF), Intermediate risk Primary Myelofibrosis (PMF), Intermediate risk Secondary Myelofibrosis
- Associated Therapies
- -
Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
- Conditions
- Interventions
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 165
- Registration Number
- NCT04884191
- Locations
- 🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸City of Hope, Duarte, California, United States
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2021-04-26
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT04858256
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 6
- Registration Number
- NCT04635059
- Locations
- 🇺🇸
Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 74
- Registration Number
- NCT04520269
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 200
- Registration Number
- NCT04404361
- Locations
- 🇺🇸
St. Jude Hospital Yorba Linda dba St. Joseph Heritage Healthcare, Orange, California, United States
🇺🇸Overlook Medical Center, Morristown, New Jersey, United States
🇺🇸Ascension St. Vincent's Riverside Hospital, Jacksonville, Florida, United States
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 25
- Registration Number
- NCT04282187
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2022-08-22
- Target Recruit Count
- 61
- Registration Number
- NCT03645824
- Locations
- 🇳🇱
NL-Rotterdam-ERASMUSMC, Rotterdam, Netherlands
🇧🇪BE-Roeselare-AZDELTA, Roeselare, Belgium
🇳🇱NL-Maastricht-MUMC, Maastricht, Netherlands
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT03601819
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 399
- Registration Number
- NCT03165734
- Locations
- 🇺🇸
The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
🇮🇳Shri Ram Cancer Centre, Mahatma Gandhi Medical College & Hospital, Jaipur, Rajasthan, India
🇮🇳Gauhati Medical College and Hospital, Guwahati, Assam, India
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
- Conditions
- Interventions
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 40
- Registration Number
- NCT02891603
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.